Antiandrogen Treatment Induces Stromal Cell Reprogramming to Promote Castration Resistance in Prostate Cancer
Hanling Wang,Ni Li,Qiuli Liu,Jiacheng Guo,Qiang Pan,Bisheng Cheng,Junyu Xu,Baijun Dong,Guanjie Yang,Bin Yang,Xuege Wang,Yongqiang Gu,Guoying Zhang,Yannan Lian,Wei Zhang,Mingyu Zhang,Tianyi Li,Yi Zang,Minjia Tan,Qintong Li,Xiaoming Wang,Zhengquan Yu,Jun Jiang,Hai Huang,Jun Qin
DOI: https://doi.org/10.1016/j.ccell.2023.05.016
IF: 50.3
2023-01-01
Cancer Cell
Abstract:Lineage plasticity causes therapeutic resistance; however, it remains unclear how the fate conversion and phenotype switching of cancer-associated fibroblasts (CAFs) are implicated in disease relapse. Here, we show that androgen deprivation therapy (ADT)-induced SPP1+ myofibroblastic CAFs (myCAFs) are critical stromal constituents that drive the development of castration-resistant prostate cancer (CRPC). Our results reveal that SPP1+ myCAFs arise from the inflammatory CAFs in hormone-sensitive PCa; therefore, they represent two functional states of an otherwise ontogenically identical cell type. Antiandrogen treatment unleashes TGF-β signaling, resulting in SOX4-SWI/SNF-dependent CAF phenotype switching. SPP1+ myCAFs in turn render PCa refractory to ADT via an SPP1-ERK paracrine mechanism. Importantly, these sub-myCAFs are associated with inferior therapeutic outcomes, providing the rationale for inhibiting polarization or paracrine mechanisms to circumvent castration resistance. Collectively, our results highlight that therapy-induced phenotypic switching of CAFs is coupled with disease progression and that targeting this stromal component may restrain CRPC.